Table 1.

Effect of compounds 4a–x against cell viability of different cell lines.

Compound	IC50 (μM)
	CNE-2	HepG2	HeLa	BEL-7402	HL-7702
4a	28.20 ± 0.43	27.81 ± 0.58	17.89 ± 0.13	36.70 ± 0.34	>100
4b	17.22 ± 0.21	12.44 ± 0.31	6.72 ± 0.22	15.38 ± 0.08	68.58 ± 2.14
4c	15.82 ± 0.56	27.60 ± 0.23	10.84 ± 0.43	21.03 ± 0.09	53.22 ± 1.36
4d	38.68 ± 0.49	35.26 ± 0.11	12.22 ± 0.08	33.59 ± 0.38	50.74 ± 1.82
4e	48.85 ± 0.05	7.62 ± 0.32	34.92 ± 0.16	15.60 ± 0.44	63.04 ± 3.06
4f	51.39 ± 0.34	25.61 ± 0.35	33.23 ± 0.21	16.90 ± 0.41	61.90 ± 1.34
4g	60.42 ± 1.02	12.50 ± 0.46	27.26 ± 0.50	36.40 ± 0.74	>100
4h	98.78 ± 0.45	44.64 ± 0.92	15.20 ± 0.29	38.53 ± 0.52	>100
4i	12.61 ± 0.24	57.84 ± 0.75	13.91 ± 0.41	44.65 ± 0.21	77.08 ± 0.96
4j	93.26 ± 0.52	39.50 ± 0.82	13.06 ± 0.08	27.45 ± 0.17	>100
4k	47.70 ± 0.23	8.47 ± 0.55	5.53 ± 0.04	48.16 ± 0.32	65.94 ± 1.48
4l	11.45 ± 0.11	35.05 ± 0.96	25.14 ± 0.10	19.95 ± 0.27	86.44 ± 3.12
4m	89.66 ± 0.27	9.94 ± 0.59	12.84 ± 0.15	23.08 ± 0.33	>100
4n	26.08 ± 0.05	50.08 ± 0.74	45.13 ± 0.09	23.79 ± 0.51	70.37 ± 2.23
4o	86.46 ± 0.13	51.28 ± 0.63	32.06 ± 0.21	14.77 ± 0.38	>100
4p	56.98 ± 0.08	48.59 ± 0.09	34.33 ± 0.32	55.29 ± 0.44	91.75 ± 1.57
4q	27.44 ± 0.72	93.76 ± 0.39	27.71 ± 0.14	22.79 ± 0.34	>100
4r	51.02 ± 0.94	31.57 ± 0.47	12.82 ± 0.13	25.86 ± 0.53	68.59 ± 1.25
4s	49.81 ± 0.49	90.08 ± 0.33	28.79 ± 0.24	25.22 ± 0.22	>100
4t	33.34 ± 0.56	22.89 ± 0.04	11.14 ± 0.15	18.78 ± 0.59	72.04 ± 1.66
4u	32.83 ± 0.16	25.36 ± 0.54	5.86 ± 0.09	18.64 ± 0.37	55.80 ± 1.38
4v	26.77 ± 0.46	16.90 ± 0.18	14.96 ± 0.21	20.52 ± 0.53	44.63 ± 2.02
4w	15.44 ± 0.21	12.07 ± 0.07	2.21 ± 0.04	14.46 ± 0.22	66.08 ± 1.84
4x	12.96 ± 0.13	8.07 ± 0.25	4.94 ± 0.13	15.83 ± 0.18	58.62 ± 2.62
DHA	88.64 ± 0.73	80.36 ± 0.84	37.40 ± 0.64	46.70 ± 0.55	>100
Cisplatin	8.75 ± 0.24	6.42 ± 0.18	1.94 ± 0.20	12.68 ± 0.33	20.76 ± 0.83